A role of aurora A tyrosine kinase inhibitor, Alisertib, in the resistance of cancer cells to Daunorubicin

被引：0
|
作者：
Yati, S. [1 ]
Novotna, E. [1 ]
Wsol, V. [1 ]
机构：
[1] Charles Univ Prague, Dept Biochem Sci, Hradec Kralove, Czech Republic
来源：
TOXICOLOGY LETTERS | 2024年 / 399卷
关键词：
D O I：
10.1016/j.toxlet.2024.07.905
中图分类号：
R99 [毒物学（毒理学）];
学科分类号：
100405 ;
摘要：
LP-42
引用
收藏
页码：S380 / S381
页数：2
相关论文
共 50 条
  • [31] A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers
    Beltran, Himisha
    Oromendia, Clara
    Danila, Daniel C.
    Montgomery, Bruce
    Hoimes, Christopher
    Szmulewitz, Russell Z.
    Vaishampayan, Ulka
    Armstrong, Andrew J.
    Stein, Mark
    Pinski, Jacek
    Mosquera, Juan M.
    Sailer, Verena
    Bareja, Rohan
    Romanel, Alessandro
    Gumpeni, Naveen
    Sboner, Andrea
    Dardenne, Etienne
    Puca, Loredana
    Prandi, Davide
    Rubin, Mark A.
    Scher, Howard I.
    Rickman, David S.
    Demichelis, Francesca
    Nanus, David M.
    Ballman, Karla V.
    Tagawa, Scott T.
    CLINICAL CANCER RESEARCH, 2019, 25 (01) : 43 - 51
  • [32] Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer (vol 36 , pg 1, 2018)
    Goff, Laura W.
    Azad, Nilofer S.
    Stein, Stacey
    Whisenant, Jennifer G.
    Koyama, Tatsuki
    Vaishampayan, Ulka
    Hochster, Howard
    Connolly, Roisin
    Weise, Amy
    LoRusso, Patricia M.
    Salaria, Safia N.
    El-Rifai, Wael
    Berlin, Jordan D.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (06) : 1158 - 1158
  • [33] Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer
    Mukherjee, A.
    Dhadda, A. S.
    Shehata, M.
    Chan, Stephen
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (13) : 2189 - 2204
  • [34] Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies
    Xiaofei Zhou
    Shubham Pant
    John Nemunaitis
    A. Craig Lockhart
    Gerald Falchook
    Todd M. Bauer
    Manish Patel
    John Sarantopoulos
    Michael Bargfrede
    Andreas Muehler
    Lakshmi Rangachari
    Bin Zhang
    Karthik Venkatakrishnan
    Investigational New Drugs, 2018, 36 : 248 - 258
  • [35] Investigation of the Radiolabelling Potential of the Aurora A Kinase Inhibitor Alisertib with Iodine-123 [123I]
    Uygur, E.
    Sezgin, C.
    Akdag, B. Y.
    Ozbey, T.
    Parlak, Y.
    Karatay, K. B.
    Gumuser, F. G.
    Muftuler, F. Z. Biber
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S782 - S782
  • [36] Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia
    Fathi, Amir T.
    Wander, Seth A.
    Blonquist, Traci M.
    Brunner, Andrew M.
    Amrein, Philip C.
    Supko, Jeffrey
    Hermance, Nicole M.
    Manning, Amity L.
    Sadrzadeh, Hossein
    Ballen, Karen K.
    Attar, Eyal C.
    Graubert, Timothy A.
    Hobbs, Gabriela
    Joseph, Christelle
    Perry, Ashley M.
    Burke, Meghan
    Silver, Regina
    Foster, Julia
    Bergeron, Meghan
    Ramos, Aura Y.
    Som, Tina T.
    Fishman, Kaitlyn M.
    McGregor, Kristin L.
    Connolly, Christine
    Neuberg, Donna S.
    Chen, Yi-Bin
    HAEMATOLOGICA, 2017, 102 (04) : 719 - 727
  • [37] Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase
    Palani, Santhosh
    Patel, Mayankbhai
    Huck, Jessica
    Zhang, Mengkun
    Balani, Suresh K.
    Yang, Johnny
    Chen, Susan
    Mettetal, Jerome
    Manfredi, Mark
    Shyu, Wen Chyi
    Ecsedy, Jeffrey A.
    Chakravarty, Arijit
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (06) : 1255 - 1264
  • [38] Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies
    Zhou, Xiaofei
    Pant, Shubham
    Nemunaitis, John
    Lockhart, A. Craig
    Falchook, Gerald
    Bauer, Todd M.
    Patel, Manish
    Sarantopoulos, John
    Bargfrede, Michael
    Muehler, Andreas
    Rangachari, Lakshmi
    Zhang, Bin
    Venkatakrishnan, Karthik
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (02) : 248 - 258
  • [39] A proteomics-based investigation on the anticancer activity of alisertib, an Aurora kinase A inhibitor, in hepatocellular carcinoma Hep3B cells
    Zhu, Qiaohua
    Luo, Meihua
    Zhou, Chengyu
    Zhou, Zhiwei
    He, Zhixu
    Yu, Xinfa
    Zhou, Shufeng
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2017, 9 (08): : 3558 - 3572
  • [40] Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation
    Becker, Kevin
    Xu, Yiqing
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2014, 5 (04): : 560 - 567
12345